← Back to patent-cliff list
CAS 97-67-6
(S)-2-hydroxysuccinic acid
Codes：IXAB-061、SUNT-010
Application context (from source-drug indications)
乳腺癌伊沙匹隆转移性乳腺癌伊沙匹隆宫颈癌伊沙匹隆前列腺癌伊沙匹隆实体瘤伊沙匹隆中性粒细胞减少伊沙匹隆胰腺神经内分泌肿瘤苹果酸舒尼替尼肾细胞癌苹果酸舒尼替尼胃肠道间质瘤苹果酸舒尼替尼骨肉瘤苹果酸舒尼替尼肉瘤苹果酸舒尼替尼淋巴瘤苹果酸舒尼替尼
Source drugs (routes using this intermediate)
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(4S,7R,8S,9S,16S,Z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)azacyclohexadec-13-ene-2,6-dione→4-((S,1E,5Z)-3-azido-6-iodo-2-methylhepta-1,5-dien-1-yl)-2-methylthiazole→(S)-2-hydroxysuccinic acid→(S)-2-(3-oxo-1,4-dioxaspiro[4.5]decan-2-yl)acetic acid→(S)-3-hydroxydihydrofuran-2(3H)-one→(S)-3-((tert-butyldimethylsilyl)oxy)dihydrofuran-2(3H)-one→(S)-3,5-bis((tert-butyldimethylsilyl)oxy)pentan-2-one→diethyl ((2-methylthiazol-4-yl)methyl)phosphonate→(S,E)-4-(3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylpent-1-en-1-yl)-2-methylthiazole→(S,E)-3-((tert-butyldimethylsilyl)oxy)-4-methyl-5-(2-methylthiazol-4-yl)pent-4-en-1-ol→(S,E)-3-((tert-butyldimethylsilyl)oxy)-4-methyl-5-(2-methylthiazol-4-yl)pent-4-enal→4-((S,1E,5Z)-3-((tert-butyldimethylsilyl)oxy)-6-iodo-2-methylhepta-1,5-dien-1-yl)-2-methylthiazole→(S,1E,5Z)-6-iodo-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-ol→tert-butyl (3R,6R,7S,8S)-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8-tetramethyl-5-oxoundec-10-enoate→tert-butyl (6R,7S,8S,12Z,15S,16E)-15-azido-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoate→tert-butyl (6R,7S,8S,12Z,15S,16E)-15-((tert-butoxycarbonyl)amino)-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoate→tert-butyl (6R,7S,8S,12Z,15S,16E)-15-((tert-butoxycarbonyl)amino)-7-((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-3,5-dioxoheptadeca-12,16-dienoate→tert-butyl (3S,6R,7S,8S,12Z,15S,16E)-15-amino-7-((tert-butyldimethylsilyl)oxy)-3-hydroxy-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoate→4-(chloromethyl)-2-methylthiazole hydrochloride→5-(benzyloxy)pentanal→pivaloyl chloride→(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol→5-(benzyloxy)-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylpentanamide→(S)-5-(benzyloxy)-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N,2-dimethylpentanamide→(S)-5-(benzyloxy)-2-methylpentan-1-ol→(S)-5-(benzyloxy)-2-methylpentanal→(S)-4-benzyl-3-propionyloxazolidin-2-one→(R)-4-benzyl-3-((2R,3S,4S)-7-(benzyloxy)-3-hydroxy-2,4-dimethylheptanoyl)oxazolidin-2-one→N,O-dimethylhydroxylamine hydrochloride→(2R,3S,4S)-7-(benzyloxy)-3-hydroxy-N-methoxy-N,2,4-trimethylheptanamide→(2R,3S,4S)-7-(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-N-methoxy-N,2,4-trimethylheptanamide→(2R,3S,4S)-7-(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-2,4-dimethylheptanal→(2-methylbut-3-en-2-yl)magnesium chloride→(5R,6S,7S)-10-(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)-3,3,5,7-tetramethyldec-1-en-4-one→(4R,5S,6S)-9-(benzyloxy)-5-((tert-butyldimethylsilyl)oxy)-2,2,4,6-tetramethyl-3-oxononanal→tert-butyl (3R,6R,7S,8S)-11-(benzyloxy)-7-((tert-butyldimethylsilyl)oxy)-3-hydroxy-4,4,6,8-tetramethyl-5-oxoundecanoate→tert-butyl (3R,6R,7S,8S)-11-(benzyloxy)-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8-tetramethyl-5-oxoundecanoate→tert-butyl (3R,6R,7S,8S)-3,7-bis((tert-butyldimethylsilyl)oxy)-11-hydroxy-4,4,6,8-tetramethyl-5-oxoundecanoate
4-methyleneoxetan-2-one→N1,N1-diethylethane-1,2-diamine→N-(2-(diethylamino)ethyl)-3-oxobutanamide→tert-butyl 3-oxobutanoate→tert-butyl 4-((2-(diethylamino)ethyl)carbamoyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate→N-(2-(diethylamino)ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide→N-(chloromethylene)-N-methylmethanaminium chloride→N-(2-(diethylamino)ethyl)-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide→5-fluoroindolin-2-one→(S)-2-hydroxysuccinic acid
N1,N1-diethylethane-1,2-diamine→tert-butyl 3-oxobutanoate→N-(2-(diethylamino)ethyl)-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide→5-fluoroindolin-2-one→(S)-2-hydroxysuccinic acid→(E)-tert-butyl 2-(hydroxyimino)-3-oxobutanoate→ethyl 3-oxobutanoate→2-(tert-butyl) 4-ethyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate→ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate→ethyl 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylate→5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
N1,N1-diethylethane-1,2-diamine→5-fluoroindolin-2-one→(S)-2-hydroxysuccinic acid→ethyl 3-oxobutanoate→ethyl 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylate→diethyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate→4-(ethoxycarbonyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic acid→ethyl (Z)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications |
|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 5-Fluoro-2-oxindole Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.